Module

Defining HBV Resistance: Interpreting and Applying Clinical Data

Source: Drug Resistance in Chronic Hepatitis B: From Definitions to Management Strategies

Defining HBV Resistance: Interpreting and Applying Clinical Data

Faculty:

Paul Martin, MD

CME CREDIT INFORMATION

Release Date: 11/05/07

Expiration Date: 11/04/08

Physicians: maximum of 2.5 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the various definitions of hepatitis B virus resistance used in various clinical studies and treatment guidelines
Explain strategies to prevent the emergence of resistance
Discuss the management of resistance in patients with chronic hepatitis B

Topics covered include:

Introduction
Hepatitis B Virus and Mechanism of Action of Anti-HBV Therapies
Development of HBV Resistance Mutations
Characteristic Events Associated With Resistance Emergence
Strategies to Detect Resistance
Resistance to Nucleos(t)ide Agents for the Treatment of HBV
Roadmap for On-Treatment Virologic Monitoring
Adding vs Switching Agents in Second-Line Therapy
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.